83 related articles for article (PubMed ID: 31508747)
1. Association of sociodemographic and clinical variables with time to start prostate cancer treatment.
Sacramento RS; Simião LJ; Viana KCG; Andrade MAC; Amorim MHC; Zandonade E
Cien Saude Colet; 2019 Sep; 24(9):3265-3274. PubMed ID: 31508747
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer outcomes and delays in care.
O'Callaghan ME; Shi Z; Kopsaftis T; Moretti K
Int Urol Nephrol; 2017 Mar; 49(3):449-455. PubMed ID: 28083860
[TBL] [Abstract][Full Text] [Related]
4. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
5. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
6. [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?].
Meunier ME; Neuzillet Y; Radulescu C; Cherbonnier C; Hervé JM; Rouanne M; Molinié V; Lebret T
Prog Urol; 2018 Sep; 28(10):475-481. PubMed ID: 29907495
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with having mammography examinations in primary health care users in Vitória, Espírito Santo, Brazil.
Silva RP; Gigante DP; Amorim MHC; Leite FMC
Epidemiol Serv Saude; 2019 Mar; 28(1):e2018048. PubMed ID: 30916239
[TBL] [Abstract][Full Text] [Related]
8. Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population?
O'Kelly F; Thomas A; Murray D; Galvin D; Mulvin D; Quinlan DM
Prostate; 2013 Sep; 73(12):1263-9. PubMed ID: 23657938
[TBL] [Abstract][Full Text] [Related]
9. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.
Krimphove MJ; Cole AP; Fletcher SA; Harmouch SS; Berg S; Lipsitz SR; Sun M; Nabi J; Nguyen PL; Hu JC; Kibel AS; Choueiri TK; Kluth LA; Trinh QD
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):125-136. PubMed ID: 30171227
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
Ito K; Yokomizo A; Tokunaga S; Arai G; Sugimoto M; Akakura K; Hasumi H; Sakai H; Ouraji A; Oki R; Kashiwagi E; Kobori Y; Hirama H; Kitoh H; Uemura H; Hakariya T; Suzuki K;
J Urol; 2020 Jan; 203(1):83-91. PubMed ID: 31430244
[TBL] [Abstract][Full Text] [Related]
13. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5.
Patel AA; Chen MH; Renshaw AA; D'Amico AV
JAMA; 2007 Oct; 298(13):1533-8. PubMed ID: 17911498
[TBL] [Abstract][Full Text] [Related]
14. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
15. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE.
Meng MV; Elkin EP; Harlan SR; Mehta SS; Lubeck DP; Carroll PR
J Urol; 2003 Dec; 170(6 Pt 1):2279-83. PubMed ID: 14634396
[TBL] [Abstract][Full Text] [Related]
16. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
17. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.
Stroup SP; Moreira DM; Chen Z; Howard L; Berger JH; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Freedland SJ
J Urol; 2017 Dec; 198(6):1309-1315. PubMed ID: 28709888
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort.
Marzouk K; Assel M; Ehdaie B; Vickers A
J Urol; 2018 Dec; 200(6):1250-1255. PubMed ID: 29886089
[TBL] [Abstract][Full Text] [Related]
19. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
[TBL] [Abstract][Full Text] [Related]
20. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
